From: Cost-effectiveness of Rotavirus vaccination in Vietnam
Epidemiological parameters | Â | Â | Â | Â |
---|---|---|---|---|
Parameters | Baseline estimates | Rangesa | Distributionsb | Sources |
5-year cumulative numbers of rotavirus gastroenteritis death (for a 2004 birth cohort) | 1,673 | 1,514–1,833c | Not varied | [38] |
Estimated age-specific incidence rate of rotavirus diarrhea associated deaths (per 100,000 per month)d | Â | Â | Not varied | [37] Estimated |
   age 0–1 month | 0.0 | Not varied |  |  |
   age 2 months | 3.5 | 2.8–4.2 |  |  |
   age 3–5 months | 3.8 | 3.0–4.5 |  |  |
   age 6–8 months | 6.5 | 5.2–7.8 |  |  |
   age 9–11 months | 12.2 | 9.7–14.6 |  |  |
   age 12–14 months | 15.3 | 12.2–18.3 |  |  |
   age 15–17 months | 14.0 | 11.2–16.8 |  |  |
   age 18–23 months | 7.9 | 6.3–9.5 |  |  |
   age 24–35 months | 3.4 | 2.7–4.1 |  |  |
   age 36–47 months | 2.9 | 2.3–3.5 |  |  |
   age 48–59 months | 2.6 | 2.1–3.1 |  |  |
Cumulative probability of primary infection (by 2 months of age), % | 3 | 0–8 | Not varied | Estimated |
Ratio of numbers of hospitalizations to deaths attributable to rotavirus gastroenteritis | 20.7 | 10.35–31.05 | Not varied | [13] |
Ratio of numbers of outpatient visits to deaths attributable to rotavirus gastroenteritis | 96.6 | 32.2–103.0 | Not varied | Assumed |
Ratios of annual incidence of different rotavirus infection outcomes (without vaccination) | Â | Â | Â | Â |
   Primary infections |  |  |  |  |
- mild vs. severe casese | 4.3 | 2.15–6.45 | Not varied | [8] |
- asymptomatic vs. severe casese | 4.1 | 2.05–6.15 | Not varied | [8] |
   Secondary infections |  |  |  |  |
- mild vs. severe casese | 21.5 | 10.8–32.3 | Triangular | [8] |
- asymptomatic vs. severe casese | 19.0 | 9.5–28.5 | Triangular | [8] |
   Secondary vs. primary severe infections | 0.167 | 0.125–0.209 | Not varied | [8] |
   Tertiary vs. primary 'any' infectionsf | 0.478 | 0.239–0.717 | Triangular | [8] |
   Quaternary vs. primary 'any' infectionsf | 0.372 | 0.186–0.558 | Triangular | [8] |
Vaccine characteristics | Â | Â | Â | Â |
Vaccine coverage (2 doses) | 94 | 90–98 | Triangular | [13] |
Serotype-specific vaccine efficacy (against severe gastroenteritis), % | Â | Â | Not varied | Â |
   G1P[8] | 90.8 | 70.5–98.2c |  | [26] |
   G3P[8], G4P[8], G9P[8] | 86.9 | 62.8–96.6c |  | [26] |
   G2P[4] and other combinations of G and P | 45.4 | 0–85.6 |  | [26] |
Vaccine efficacy against severe gastroenteritis, % (adjusted for the serotype distribution) | 77 | 43–99 | Triangular | Estimated |
Vaccine efficacy against mild gastroenteritis, % (not adjusted for the serotype distribution) | 41 | 21–62 | Triangular | Estimated |
Costs g | Â | Â | Â | Â |
   Vaccination costs |  |  |  |  |
Vaccine price (per dose) | 5 | 0.1–10 | Triangular | Assumed |
Vaccine wastage rate, % | 10 | 0–20 | Triangular | Assumed |
Delivery costsh (per dose) | 0.7 | 0.35–1.05 | Triangular | Estimated |
   Disease treatment costs |  |  |  |  |
Outpatient visit (per episode) | 3.49 | 2.88–4.11 | Triangular | [13] |
Hospitalization (per episode) | 19.97 | 14.98–24.96 | Triangular | [13] |
   Direct nonmedical costs |  |  |  |  |
Transport | Â | Â | Â | Â |
- for outpatient visit | 0.69 | 0.52–0.86 | Triangular | [13] |
- for hospitalization | 4.46 | 3.35–5.58 | Triangular | [13] |
Caregiver's time | Â | Â | Â | Â |
- for outpatient visit | 2.82 | 2.12–3.53 | Triangular | [13] |
- for hospitalization | 7.86 | 5.90–9.83 | Triangular | [13] |
Discount rate, % | 3 | 0–6 | Not applicable | Assumed |
Disability weight for diarrhoeal episode | 0.119 | 0.086–0.152 | Triangular | [47] |